ArticleCancer science2008
Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis.
Article in Cancer science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Intraperitoneal blue LED irradiation as a potential approach to suppress gastric cancer peritoneal dissemination in a murine model.Scientific reports · 2026Article
- Krukenberg Tumors: Does Surgical Resection Improve Survival?Indian journal of surgical oncology · 2025Article
- CircWHSC1 promotes ovarian cancer progression by regulating MUC1 and hTERT through sponging miR-145 and miR-1182.Journal of experimental & clinical cancer research : CR · 2019Article
- Molecular factors regulating E-cadherin expression in urothelial bladder cancer and their correlations with the clinicopathological features.Molecular biology reports · 2017Article
- Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast.Geburtshilfe und Frauenheilkunde · 2017Article
- HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.Cellular oncology (Dordrecht, Netherlands) · 2017Article
- Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.Oncotarget · 2016Article
- Angiopoietin-like protein 2 as a potential biomarker for colorectal cancer.Molecular and clinical oncology · 2015Article
- S100A4 silencing blocks invasive ability of esophageal squamous cell carcinoma cells.World journal of gastroenterology · 2012Article
- Article
- The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression.Virchows Archiv : an international journal of pathology · 2011Article
- Slug down-regulation by RNA interference inhibits invasion growth in human esophageal squamous cell carcinoma.BMC gastroenterology · 2011Article
- The detection, treatment, and biology of epithelial ovarian cancer.Journal of ovarian research · 2010Article
- Pioglitazone Suppresses Urothelial TumorigenesisCancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical observations of cases of ovarian metastasis suggest that there may be a unique mechanism underlying ovarian-specific metastasis. This study was undertaken to establish an in vivo model of metastasis to the ovary, and to investigate the mechanism of ovarian-specific metastasis. We examined the capacity for ovarian metastasis in eight different human carcinoma cell lines by implantation in female NOD/SCID mice transvenously and intraperitoneally. By transvenous inoculation, only RERF-LC-AI, a poorly differentiated carcinoma cell line, frequently demonstrated ovarian metastasis. By intraperitoneal inoculation, four of the eight cell lines (HGC27, MKN-45, KATO-III, and RERF-LC-AI) metastasized to the ovary. We compared E-cadherin expression among ovarian metastatic cell lines and others. All of these four ovarian metastatic cell lines and HSKTC, a Krukenberg tumor cell line, showed E-cadherin down-regulation and others did not. E-cadherin was then forcibly expressed in RERF-LC-AI, and inhibited ovarian metastasis completely. The capacity for metastasizing to the other organs was not affected by E-cadherin expression. We also performed histological investigation of clinical ovarian-metastatic tumor cases. About half of all ovarian-metastatic tumor cases showed loss or reduction of E-cadherin expression. These data suggest that E-cadherin down-regulation may be involved in ovarian-specific metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.